p16INK4a Expression (p16 / CDKN2A)
Tumor suppressor protein encoded by the CDKN2A gene that binds CDK4/6, preventing retinoblastoma (Rb) phosphorylation and arresting the cell cycle.
Standard vs. Optimal Reference RangesRelative Units
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Analyte is within optimal non-reactive clinical parameters.
Low baseline expression in PBMC
General reference distribution across unselected commercial populations.
Minimal age-adjusted expression
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Induced progressively by cumulative DNA damage, oncogenic signaling, and oxidative stress; expression in T-cells increases exponentially with chronological age.
Differential Diagnosis
Elevated Levels (p16 / CDKN2A High)
- •High cellular senescence burden
- •Accelerated biological aging of T-lymphocytes
- •Chronic chemotherapy-induced senescence
Low Levels (p16 / CDKN2A Low)
- •Low senescent cell burden
- •Youthful cellular regenerative potential
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for p16 / CDKN2A
- Targeted organ system imaging or functional dynamic testing related to cyclin-dependent kinase inhibitor & senescence
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of p16INK4a Expression - The New England Journal of Medicine (2021). PMID: 34090124
- [2]p16 / CDKN2A Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35322901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate p16INK4a Expression (p16 / CDKN2A) into overall healthspan optimization.